Ser247

Site Information
GALsNsEsIPTIDGL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 449851

In vivo Characterization
Methods used to characterize site in vivo:	[32P] bio-synthetic labeling ( 5 ) , mass spectrometry ( 1 , 2 , 4 ) , mutation of modification site ( 5 ) , peptide sequencing ( 5 ) , phosphopeptide mapping ( 5 )
Disease tissue studied:	HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:	breast ( 1 ) , COS (fibroblast) ( 5 ) , Jurkat (T lymphocyte) ( 2 ) , K562 (erythroid) ( 4 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
3	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
4	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
5	Itoh F, et al. (2001) Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. EMBO J 20, 4132-42 11483516 Curated Info